Mersana Therapeutics Price to Book Ratio 2016-2021 | MRSN

Historical price to book ratio values for Mersana Therapeutics (MRSN) over the last 10 years. The current price to book ratio for Mersana Therapeutics as of October 15, 2021 is 3.02.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Mersana Therapeutics Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-15 8.49 3.10
2021-06-30 13.58 $2.74 4.96
2021-03-31 16.18 $2.87 5.64
2020-12-31 26.61 $3.31 8.03
2020-09-30 18.62 $3.70 5.03
2020-06-30 23.40 $4.00 5.85
2020-03-31 5.83 $1.31 4.44
2019-12-31 5.73 $1.73 3.32
2019-09-30 1.58 $1.94 0.81
2019-06-30 4.05 $2.27 1.78
2019-03-31 5.26 $2.60 2.02
2018-12-31 4.08 $0.38 10.78
2018-09-30 10.00 $1.29 7.76
2018-06-30 17.86 $1.98 9.04
2018-03-31 15.77 $2.47 6.38
2017-12-31 16.43 $3.07 5.34
2017-09-30 17.29 $3.68 4.70
2017-06-30 13.97 $15.29 0.91
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.609B $0.001B
Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00